Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APL 1030

Next Previous
Drug Profile

APL 1030

Alternative Names: APL-1030; APL-1030-IT

Latest Information Update: 22 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apellis Pharmaceuticals
  • Class Neuroprotectants; Proteins
  • Mechanism of Action Complement C3 inhibitors; Complement C3b inactivator protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Neurodegenerative disorders

Most Recent Events

  • 14 May 2026 Apellis Pharmaceuticals has been acquired by Biogen
  • 28 Jul 2025 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA (Intrathecal, Infusion)
  • 28 Mar 2023 Apellis Pharmaceuticals has patent protection for APL 2006 and APL 1030

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top